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Abstract: Bile is a unique body fluid synthesized in our liver. Enterohepatic circulation preserves bile in our body through its efficient
synthesis, transport, absorption, and reuptake. Bile is the main excretory route for bile salts, bilirubin, and potentially harmful
exogenous lipophilic substances. The primary way of eliminating cholesterol is bile. Although bile has many organic and inorganic
contents, bile acid is the most physiologically active component. Bile acids have a multitude of critical physiologic functions in our
body. These include emulsification of dietary fat, absorption of fat and fat-soluble vitamins, maintaining glucose, lipid, and energy
homeostasis, sustenance of intestinal epithelial integrity and epithelial cell proliferation, reducing inflammation in the intestine, and
prevention of enteric infection due to its antimicrobial properties. But bile acids can be harmful in certain altered conditions like
cholecystectomy, terminal ileal disease or resection, cholestasis, duodenogastric bile reflux, duodenogastroesophageal bile reflux, and
bile acid diarrhea. Bile acids can have malignant potentials as well. There are also important diagnostic and therapeutic roles of bile
acid and bile acid modulation.
Keywords: bile, function of bile acids, diagnostic and therapeutic roles of bile acids, cholestasis, bile acid diarrhea

Introduction
Bile (also called gall) is a unique dark green to yellowish-green, thick, sticky, and slightly alkaline fluid produced by the
liver, stored and concentrated in the gallbladder, and then released into the second part of the duodenum. It subsequently
travels to the terminal ileum, where it gets absorbed by the ileal enterocytes and returns back to the liver via the portal
venous system in a process known as enterohepatic circulation. Bile has a unique composition and many physiologic
functions. Utilizing the functional aspects of bile, bile acid, and its modulation are used therapeutically and in different
diagnostic tests. We will discuss the various compositions of bile, physiology of bile, functions of bile, variation of serum
levels of bile acids, lithogenic bile, bile acid metabolism in altered conditions, duodenogastric bile reflux, duodenogas
troesohageal bile reflux, cholestasis, bile acid diarrhea, bile acid and malignancy, utilization of bile acid and its
modulations in diagnostic tests and treatments.

Composition of Bile
It reflects the functional status of hepatocytes (which constitute 65% of the liver cell population) and cholangiocytes
(which include 5% of the liver cell population). Approximately 95% of bile is water, and 5% is a complex mixture of
organic and inorganic solutes that include (1) electrolytes (sodium, potassium, calcium, chloride, and bicarbonate), (2)
endogenous constituents like bile acid and bile salts, bilirubin, cholesterol, phospholipid, carbohydrates, proteins,
enzymes, steroids, amino acids, vitamins, immunoglobulin A (IgA), immunoglobulin G (IgG) cytokines, porphyrins,
mineral salts, trace elements, and heavy metals, and (3) exogenous substances like xenobiotics, drugs and environmental
toxins.1 Bile acids are wedge-shaped steroid acids formed by removing the last three carbon atoms of cholesterol’s
terminal aliphatic side chain.2 They are amphipathic molecules having a hydrophilic side and a hydrophobic side
(Figure 1). Cholic acid and chenodeoxycholic acid (CDCA) are the primary bile acids synthesized by hepatocytes in
Clinical and Experimental Gastroenterology 2022:15 105–120
Received: 30 January 2022
Accepted: 3 July 2022
Published: 20 July 2022

105

© 2022 Ahmed. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Dovepress

Ahmed

Figure 1 Bile acid.

the liver either by classic or alternative pathways. 95% of bile acid synthesis occurs in the classical pathway that involves
cytochrome P450-mediated oxidation of cholesterol and 14 enzymatic steps; the most important one is the rate-limiting
enzyme cholesterol 7 alpha-hydroxylase (CYP7B1) which causes hydroxylation of the 7th steroid nucleus of cholesterol.
The cholic acid synthesis also requires sterol 12α-hydroxylase (CYP8B1). 5% of bile acid synthesis occurs via an
alternate pathway or acidic pathway, which involves the inner mitochondrial membrane enzyme 27-hydroxylase
(CYP27A1) widely present in all tissues in the body.3 Transport of cholesterol to mitochondrial CYP27A1 by steroido
genic acute regulatory protein (StarD1), hydroxylation of cholesterol to 3 oxysterols (26-hydroxycholesterol, 25hydroxycholesterol, and 24-hydroxycholesterol), and subsequent 7α-hydroxylation of these oxysterols by CYP7B1 are
the main steps of the alternate pathway. The ultimate controlling enzyme of cellular oxysterol levels is CYP7B1.
Oxysterols are subsequently transported back to the hepatocytes and are converted to bile acids.4 The primary bile
acids are lipid-soluble and typically get conjugated to taurine or glycine in hepatocytes to form water-soluble conjugated
bile acids (taurocholic acid/taurochenodeoxycholic acid or glycocholic acid/glycochenodeoxycholic acid), also called bile
salts before secretion into the biliary canaliculi. Deoxycholic acid, lithocholic acid (ie, dehydroxylated chenodeoxycholic
acid), and ursodeoxycholic acid are the secondary bile acids formed in the colon by bacterial deconjugation and
dehydroxylation of primary bile acids. Usually, both primary and secondary bile acids are conjugated to taurine or
glycine.5 In humans, the total amount of bile acids is about 2 to 3 grams. Cholic acid, chenodeoxycholic acid, and
deoxycholic acid constitute 95% of the bile acid pool, whereas lithocholic acid, ursodeoxycholic acid, and other minor
bile acids contribute only 5% of the bile acid pool. The most concentrated organic solutes in bile are bile salts. Bile
becomes concentrated when the gallbladder absorbs water and electrolytes. Cholesterol and phospholipids (lecithin) are
secreted from the hepatocytes into the bile in the form of small spherical membranous vesicles, also called unilamellar
vesicles. Cholesterol and lecithins are virtually water-insoluble, and bile acids make them soluble because of their
hydrophilic and hydrophobic sides. Initially, the bile acids aggregate to form simple micelles when the concentration
exceeds the critical micellar concentration (CMC), ie, ~ 2 mmol/L. Each simple micelle appears like a disc with
a diameter of about 3 nm, with its hydrophobic side facing inward and a hydrophilic side facing outward. In the
gallbladder, cholesterol becomes solubilized within the inner hydrophobic portion, and phospholipid becomes incorpo
rated into the outer hydrophilic part of the simple micelle to form a mixed micellar solution. Each mixed micelle
(Figure 2) is about 4 to 8 nm in diameter and can solubilize cholesterol three times more than a simple micelle. One mole

Figure 2 Mixed micelle.

106

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/CEG.S360563

DovePress

Clinical and Experimental Gastroenterology 2022:15

Dovepress

Ahmed

of bile salt can solubilize two moles lecithin.6 The cholesterol solubility is maximum when the molar ratio of
phospholipid to bile acids varies between 0.2 to 0.3.7

Physiology of Bile
Bile is a lipid-rich complex iso-osmotic fluid primarily synthesized and secreted by hepatocytes into the biliary canaliculi at a rate
of about 500 mg per day. The intercellular junctions (tight, gap, and adherens junctions) attach hepatocytes to form liver plates.
The tight junctions also called the blood-biliary barrier, keep biliary canalicular bile away from blood circulation.8 Transport
proteins are at the hepatocytes’ basolateral (sinusoidal) and apical (canalicular) membranes. Exogenous and endogenous
substances seen in the bile are transported from the blood into the hepatocytes through the basolateral membrane, and
subsequently, they are secreted from the hepatocytes into the biliary canaliculi (~1 μm in diameter) through the apical membrane.
Gap junctions can allow intercellular communication and enable the contraction of biliary canaliculi from the centrilobular zone to
the periportal zone.9 Thus, both tight junctions and gap junctions are crucial in biliary secretion, and impairment of the functions of
these junctions may result in intrahepatic cholestasis. Hepatocytes produce bile by secreting bile salts, conjugated bilirubin,
protein, cholesterol, phospholipid ions, and water into the biliary canaliculi through the canalicular membrane considered as the
central secretory apparatus. Transporting bile salts into the biliary canaliculi is an active process against the concentration gradient
with the help of transport proteins’ energy and is the primary stimulus for bile formation. Water and inorganic ions follow the
osmotic and electrochemical gradient. The canalicular bile flows into the intrahepatic bile ducts (ductal bile), where the
cholangiocytes further modify the composition of bile as they secrete bicarbonate-rich fluid. About 50% of the hepatic component
of bile flow (approximately 225 mL per day) depends on the osmotic force of bile acids, also called bile acid-dependent fraction
(BADF) of bile, and the rest is independent of the osmotic force of bile acids also called bile acid independent fraction (BAIF) of
bile.10 Glutathione and bicarbonate prompt BAIF. A certain proportion of bile secreted between meals flows directly through the
hepatic ducts and the common bile duct into the duodenum. However, most hepatic bile passes into the gall bladder even during
the postprandial period for storage and concentration.11 The gallbladder (GB) concentrates the bile 5 to 18 times the strength of its
original secretion under fasting conditions.
Bile secretion and GB function are under neurohormonal control. Secretin, cholecystokinin (CCK), glucagon, and
sulfated gastrin can increase the amount of bile volume and inorganic ion excretion into the bile. Secretin increases
bicarbonate-rich fluid secretion by binding to its receptors at the basolateral side of cholangiocytes. This process involves
efflux of chloride through activation of chloride channels and bicarbonate secretion via AE2/SLC4A2-mediated CL/HCO
exchange.12 Secretin-mediated bile flow is increased by vasoactive intestinal polypeptide (VIP) and decreased by
dopamine, non-sulfated gastrin, and somatostatin. CCK can cause GB contraction and sphincter of Oddi relaxation.
Acetylcholine through the vagus nerve helps maintain GB muscle tone.13
Catecholamines can increase bile flow by binding to beta receptors in the biliary tract, although the exact mechanism
is unknown. Certain bile acids can produce a higher volume of bile, also called choleretic bile acids, and ursodeoxycholic
acid is a classic example. The total bile flow is about 800 to 1000 mL of bile every day, ie, 40 to 50 mL/hour before
concentrated in the gallbladder. Hepatocytes secrete 75% of bile, and cholangiocytes secrete 25% of bile.14 After
a standard meal, the gallbladder contracts to empty the concentrated bile into the duodenum. Bile flows through the
duodenum and jejunum into the ileum. An apical sodium-dependent bile acid transporter (ASBT) on the ileal enterocytes
in the terminal ileum actively absorbs 95% of luminal bile acids. Bile acid then goes to the basolateral membrane of ileal
enterocytes to be transported into the portal venous system by an organic solute transporter α/β heterodimer. Bile acids
travel through the portal circulation into the liver. Bile acids and bilirubin are transported into the hepatocytes across the
sinusoidal membrane with the help of sodium taurocholate cotransporter (NTCT) and organic anion transporters, thus
establishing the enterohepatic circulation. Then, using the bile salt export pump (BSEP), bile acids are secreted across the
canalicular membrane in an ATP-dependent fashion into the biliary canaliculi.15
Thus, the enterohepatic circulation (Figure 3) is an anatomical, physiological, and partly vascular process that involves the
transport of bile acids, bilirubin, drugs, and substances from the liver into the bile, followed by their passage into the intestinal
lumen, absorption across the terminal ileal mucosa into the portal circulation and finally, uptake into the hepatocytes. Terminal
ileal absorption of bile acids leads to the accumulation of 2 to 3 gm of bile acid called “bile acid pool.” This cycle happens 10 to 12
times per day and can handle 20 to 30 grams of bile acids per day. Each time, small amounts of bile salt escape terminal ileal
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Figure 3 Enterohepatic circulation.

absorption (400 to 800 mg daily) and enter into the colon, where some of the secondary bile acids formed by bacterial
deconjugation and dehydroxylation are absorbed.16 When secondary bile acids get absorbed through the colon mucosa passively,
they can damage the DNA of colonic epithelial cells, and epidemiological studies showed a correlation of increased fecal
secondary bile acid concentration and increased incidence of colon cancer. The gut cannot absorb about 5% of bile acids, and
hepatic biosynthesis can replenish this loss. Nonsteroidal anti-inflammatory drugs, antibiotics, warfarin, digoxin, opioids, and
hormones are secreted from the hepatocytes into the bile and undergo enterohepatic circulation. Many lipophilic xenobiotics can
also utilize enterohepatic circulation with repeated damage to the liver. Antibiotics may reduce enterohepatic circulation by
suppressing intestinal bacterial deconjugation and dehydroxylation.
Within the ileal enterocytes, bile acids activate the nuclear receptor farnesoid X (FXR) and membrane-bound
G-protein-coupled bile acid receptor 1, also called Gpbar1, or Takeda G protein-coupled receptor or triglyceride receptor
5 (TGR5). The primary bile acids chenodeoxycholic acid and cholic acid are the most potent FXR activator/endogenous
ligand, followed by deoxycholic acid and lithocholic acid.17 On the other hand, the secondary bile acids lithocholic acid
and deoxycholic acid are the most potent activators of TGR5.18 FXR and TGR5 are co-expressed in the L cells present in
the epithelial layer of the ileum and colon.
FXR activation in the terminal ileum induces the production of fibroblast growth factor 19 (FGF19), which is a bile acidinduced ileal hormone that is secreted into the portal venous system and circulates to the hepatocytes in the liver where it
binds to the cell surface receptor complex of β Klotho protein and fibroblast growth factor receptor 4 (FGFR4) complex.
Activation of this complex reduces bile acid synthesis by downregulating CYP7A1 and CYP8B1 expression.19 This
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feedback inhibition is the principal mechanism of control of bile acid biosynthesis. FGF19 can also induce protein and
glycogen synthesis but inhibits glycolysis, gluconeogenesis, and lipogenesis in the liver. A low FGF19 level has been found
in primary bile acid diarrhea.20
Different organs, like the small intestine, colon, liver, gallbladder, kidney, and adrenal cortex, express FXR-α.
Activation of intestinal FXR can improve insulin sensitivity and energy metabolism to prevent diabetes, non-alcoholic
fatty liver disease (NAFLD), and obesity.
Hepatic FXR controls the expression of bile acid transporters to keep low levels of intracellular bile acids. It
decreases bile acid transport from the portal circulation by inhibiting the expression of NTCT and increases the excretion
of intracellular bile acids into the biliary canaliculi by activating the expression of BSEP. Hepatic FXR also increases the
expression of an atypical nuclear receptor, which subsequently decreases bile acid synthesis by suppressing the
transcription of cholesterol 7a-hydroxylase. Thus, enterohepatic FXR plays a significant role in bile acid synthesis,
excretion, and detoxification.21 Hepatic FXR protects the liver and suppresses the development of hepatocellular cancer
in multiple ways: preventing hepatic apoptosis and inflammation by modulating NF-κB and cytokine-inducible SH2containing protein, promoting hepatic repair and regeneration, decreasing hepatic fibrosis, activating the expression of
short heterodimer partner (SHP), and regulating bile acid homeostasis.22
Although many human tissues detect TGR5, it is highly expressed in the intestine, liver, and gall bladder epithelial cells and
exerts its paracrine effects. In the intestine, bile acid-induced activation of TGR5 protects intestinal barrier function, reduces
inflammation, and stimulates glucagon-like peptide-1 (GLP-1) secretion from enteroendocrine L-cells in the ileocolonic mucosa.
Usually, rapid activation of L-cells occurs after a meal due to the release of glucose-stimulated insulinotropic peptide (GIP) and
gastrin-releasing peptide (GRP) from the proximal small bowel. Activation of TGR5 in pancreatic β cells in pancreatic islets can
release insulin directly.23 TGR5 is found close to cystic fibrosis transmembrane conductance regulator (CFTR) and ASBT in
epithelial cells in the gall bladder. TGR5 activation stimulates chloride secretion into the bile through CFTR, causes smooth
muscle relaxation, and enhances refilling of the gall bladder.24 In the liver, only Kupffer cells, sinusoidal endothelial cells, and
cholangiocytes (not hepatocytes) express TGR5. It plays a vital role in hepatic lipid metabolism as it prevents fasting-induced
hepatic steatosis by decreasing fatty acid uptake in the liver and increasing beta-oxidation of fatty acids in the liver. It stimulates
nitric oxide synthesis in sinusoidal endothelial cells, mediates paracrine vasodilation, and thus connects bile acids with hepatic
hemodynamics.25
TGR5 activation stimulates thyroid hormone deiodinase 2 (Dio2) in adipose tissue, converting T4 to T3. Thus,
activation of TGR5 regulates glucose and lipid metabolism and homeostasis of energy.26,27 Intestinal bacteria degrade
bilirubin to urobilinogen. The gut absorbs 50% of urobilinogen to get excreted in the urine, and the rest of urobilinogen
gets converted to stercobilinogen, which gives the stool color brown.28
Because of efficient enterohepatic circulation and 70 to 90% of hepatic first-pass metabolism, the fasting level of serum
bile acids in the systemic circulation remains low (2–3 µmol/L) compared to that in the portal circulation (10–18 µmol/L). In
the postprandial period (15 to 60 minutes after meals), the level of bile acid increases not only in the portal circulation (37−49
µmol/L) but also in the systemic circulation (5–6 µmol/L) as a small amount of bile acids escape the enterohepatic
circulation.29 The serum bile acids bind to serum albumin and get filtered through the glomerular basement membrane
(about 100 μmol/day). However, only 1–2 μmol of bile acids get excreted through the urine daily because of efficient
proximal tubular reuptake and reabsorption utilizing ASBT and α/β heterodimer transporters in renal epithelial cells.30,31

The Function of Bile in the Liver
Bile helps drain metabolic waste products from the liver into the duodenum. It also acts as a route for cholesterol, bile salts, and
bilirubin excretion. Toxins from liver detoxification processes and certain metals such as copper, zinc, and mercury get excreted
through bile. Hepatic bile acid FXR inhibits hepatic phosphoenolpyruvate (PEP) carboxykinase activity (which converts
oxaloacetate to phosphoenolpyruvate) and stimulates glycogen synthetase activity. Thus, bile acid FXR signaling inhibits
gluconeogenesis, stimulates glycogen synthesis, enhances insulin sensitivity, and controls glucose metabolism.32 Hepatic bile
acid-TGR5 signaling regulates lipid metabolism and prevents hepatic steatosis.
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The Function of Bile in the Intestine
The primary function of bile acids in the intestine is digestion and absorption of fat (cholesterol, triglycerides), fat-soluble vitamins
(vitamins A, D, E, K), other lipophilic nutrients, iron, calcium, and provitamin beta-carotene. Bile acids have detergent-like
emulsifying power to break dietary large fat globules into tiny emulsion droplets, thus significantly increasing their surface area
for lipase action.33 As a result, lipase can digest the emulsified fat quickly. Bile acts as a suitable medium allowing the interaction
of fat and fat-splitting enzymes. Bile acid micelles also carry the digested fat to the intestinal brush border, facilitating absorption.
Deoxycholic acid may affect intestinal smooth muscle activity, and chenodeoxycholic acid is potent in causing intestinal
secretion.34 Bile acids have a role in maintaining epithelial integrity and epithelial cell proliferation. They can also reduce
intestinal inflammation and establish normoglycemia through activation of TGR5, as mentioned before. Bile acids can control
cholesterol, triglycerides, glucose, energy hemostasis, bile acid synthesis, and enterohepatic circulation by activating different
signaling pathways. Bile salts also have bacteriostatic and potent antimicrobial activity against invasive microorganisms in the
gut. They can stimulate mucin secretion from gut epithelial cells, inhibit bacterial adhesion to the gut mucosa, and bind enterotoxin
in the lumen of the gut. Bile acids can also stimulate innate immunity in the liver and intestine by activating FXR and TGR5 in
macrophages, dendritic cells, and natural killer T cells. They play an essential role in maintaining the microbial ecology of the
intestine. Bacterial colonization can increase with the change in the concentration of bile salts. In cirrhosis of the liver, small
intestinal bacterial overgrowth can occur due to decreased intraluminal bile salts.35

Variation in Serum Bile Acids
A mild increase in serum bile acids occurs following meals. But the marked elevation of serum bile acids can occur in
various liver diseases like acute viral hepatitis, cirrhosis of the liver, cholestasis, cholangitis, liver failure, hemochroma
tosis, portal vein thrombosis, Budd-Chiari syndrome, portosystemic shunt, and Wilson disease. An increased serum bile
acid level in bariatric surgery like sleeve gastrectomy improves metabolism and weight loss by activating TGR5 and
FXR receptors. In cholestatic liver diseases, the serum bile acid can be as high as 100 times the average concentration,
and this increase is mainly due to conjugated bile acids.36 Increased bile acids in hepatocytes, as seen in cholestasis, can
cause hepatocyte injury because of its inherent detergent activity and are partly responsible for hepatotoxicity in
cholestatic liver diseases.37 Elevated serum bile acids (both fasting and postprandial) have high sensitivity (93%) for
the detection of cirrhosis of the liver in the presence of normal transaminases.38 In genetic liver disorders like Gilbert
syndrome, Crigler-Najjar syndrome, and Dubin-Johnson syndrome, serum bile acid can be normal.
Diminished serum bile acids can be seen in fasting, delayed gastric emptying, and terminal ileal disease or resection.

Lithogenic Bile
This means that the bile tends to form gallstones. Bile becomes lithogenic when the bile gets supersaturated with cholesterol
either due to hypersecretion of biliary cholesterol or decreased bile acid output.39 Cholesterol solubility in the bile depends on
two variables: bile salt-lecithin ratio and the total lipid ((bile salts + lecithin + cholesterol) concentration in the bile. The
lithogenic index is the ratio of the actual cholesterol present in the bile to the maximal cholesterol dissolvable in that bile
sample. The suspicion of “lithogenic bile” comes in the setting of cholesterol gallstone disease, biliary microlithiasis, biliary
sludge, and biliary microcrystal disease. Several medical and surgical conditions can be associated with the formation of
lithogenic bile. These include obesity, pregnancy, genetic predisposition, high-calorie diet, oral contraceptive pills, certain
medications like clofibrate, ileal disease, or resection with bile salt depletion. Lithogenic bile stimulates the gallbladder to
hypersecrete mucus that promotes the formation of cholesterol microcrystals and gallstones.

Bile Acid Metabolism in Altered Conditions
Cholecystectomy
Gallbladder cholangiocytes secrete high levels of FGF19 into bile. FGF19 plays a vital role in the negative feedback
regulation of bile acid synthesis. As a result, cholecystectomy doubles the production of bile acids.40 Because of the
absence of the gallbladder, there is a continuous flow of bile salts into the intestine. Increased entry of primary bile acids
into the intestine increases the pool size of secondary bile acids, particularly deoxycholic acid, due to increased exposure
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of primary bile acids to bacterial deconjugation and dehydroxylation in the colon.41 Deoxycholic acid irritates the colon
mucosa, causing water and electrolytes secretion and increasing colon motility, shortening colon transit time.42 Up to
12% of post-cholecystectomy patients develop chronic diarrhea (ie, ≥ 3 liquid stools per day for >4 weeks), usually a few
weeks after surgery, ie, post-cholecystectomy diarrhea.43

Terminal Ileal Resection or Terminal Ileal Disease
Terminal ileum is 3 to 4 cm long. It is responsible for the active absorption of 95% of luminal bile acids and vitamin B12 and fat not
yet absorbed in the proximal small bowel. Terminal ileal resection may be necessary if there is a fibrotic stricture not amenable to
endoscopic intervention, symptomatic internal or enterocutaneous fistula of the terminal ileum due to Crohn’s disease, terminal
ileal disease refractory to biologic agents, neoplastic involvement of the terminal ileum due to neuroendocrine tumor or
adenocarcinoma, uncontrolled terminal ileal infection and uncontrolled terminal ileal bleeding due to ulcer or injury.44 As
mentioned before, short ileal disease or resection of less than 100 cm may cause bile acid-induced diarrhea or choleraic diarrhea by
unabsorbed bile salts. Long ileal disease or more than 100 cm resection may cause bile salt deficiency and fat malabsorption,
leading to steatorrhea. Colonic bacteria can also secrete lipases that degrade unabsorbed dietary triglycerides and release hydroxy
fatty acids, increasing colonic secretion.45 As little as 10 cm of ileal disease or resection can derange bile acid metabolism with an
increased propensity to develop cholelithiasis and urolithiasis.46 Cholelithiasis may include both cholesterol and pigment stones.
Bile acid malabsorption may cause supersaturation of bile with cholesterol, leading to cholesterol gallstones in many patients.
Pigment gallstones can also be formed as malabsorbed bile acids in the colon solubilize unconjugated bilirubin promoting
increased absorption of conjugated bilirubin from the colon and ultimately increased rate of bilirubin secretion into the bile.47 Bile
acid deficiency may lead to fat malabsorption, and unabsorbed long-chain fatty acid in the colon binds to calcium and magnesium
to create soaps. Normally oxalate binds to calcium to form insoluble and unabsorbable calcium oxalate. Calcium is now
unavailable; oxalate binds to sodium to form soluble and absorbable sodium oxalate, resulting in enteric hyperoxaluria and
calcium oxalate renal stone.48

Duodenogastric Bile Reflux (DGR)
Mild retrograde bile flow from the duodenum into the stomach can be physiological. Although mild bile reflux may not
cause any gastric injury, excessive bile reflux may cause alkaline gastritis. Bile acids can directly damage the gastric
surface epithelium and disrupt the mucosal barrier leading to back-diffusion of hydrogen ions and histamine-mediated
vascular response to hyperemia and edema. Patients can develop chronic gastritis, gastric ulceration, gastric atrophy, and
intestinal metaplasia. Intestinal metaplasia can be pronounced in the presence of H. pylori infection.49 Bile acid is toxic
to the gastric mucosa and is also considered a risk factor for the development of gastric cancer.50 Primary DGR can occur
due to antroduodenal motility disorder. Secondary DGR generally follows surgical alteration of gastroduodenal anatomy
(pyloroplasty, distal gastric resection with Billroth I or II reconstruction) or cholecystectomy.51 Patients with DGR may
present with dyspepsia, nausea, and bilious emesis. Upper endoscopy may show the presence of bile in the stomach, and
biopsy may reveal the presence of chemical gastritis. DGR can be quantified by diisopropyl iminodiacetic acid (DISIDA)
scan, hydroxy iminodiacetic acid (HIDA) scan, or 24-hour intragastric bile monitoring with the Bilitec device.52
Excessive DGR can also promote the development of duodenogastroesophageal (DGER) non-acid reflux.
DGER alone may not cause damage to the esophageal mucosa, but in combination with acid reflux, it may cause significant
esophageal mucosal injury, including the development of Barrett’s esophagus.53 Bile reflux into the esophagus is not uncommon
in patients with Barrett’s esophagus and early esophageal carcinoma (EAC). Conjugated bile acids (taurocholic acid and
glycocholic acids) can increase the invasiveness and metastasis of EAC by activating sphingosine 1-phosphate receptor 2
(S1PR2).54 Bilitec is the investigation of choice for diagnosing DGER, and it should always be done in combination with
a 24 hour esophageal pH study.55 The treatment of DGR is nonspecific, challenging, and unsatisfactory. Prokinetic agents can
decrease DGR by improving gastric emptying. PPI can reduce the potentially harmful effect of DGER by reducing gastro
esophageal acid reflux. In the case of cholecystectomy, bile acid binders like cholestyramine can be helpful. A duodenal switch
operation should be considered in patients with transpyloric DGR not responding to medical therapy.56 DGER can be treated by
Nissen Fundoplication if lifestyle modification, PPI, and baclofen fail.57
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Cholestasis
Is a condition in which there is diminished bile flow either due to impairment of bile formation or intra-hepatic or
extra-hepatic biliary obstruction. As a result, there is the retention of bile acids, bilirubin, and other substances
normally get excreted in the bile. In cholestasis, serum bile acids are generally greater than 10 µmol/L. Because of
their detergent-like activity, retained bile acids in the liver can cause membrane dysfunction and membrane injury to
hepatocytes and cholangiocytes. Retained bile acids can injure all biological membranes throughout the body.
Retained cholesterol in the liver can cause dysfunction of integral membrane proteins due to increased cholesterol
deposition in the membranes. In cholestasis, conjugation of unconjugated bilirubin to conjugated bilirubin continues,
and as a result, conjugated hyperbilirubinemia is one of the principal signs of cholestasis. Chronic cholestasis can
lead to hepatic fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and cholangiocarcinoma.58 High concentrations of
intrahepatic bile acids can damage the hepatocyte DNA leading to increased mutation of tumor suppressor genes and
oncogenes. In a large prospective study, Stepien et al found an association of HCC and increased concentrations of
major circulating bile acids with a higher proportion of taurine-conjugated bile acids from a few years to the
development of HCC. This study may indicate that an altered bile acid metabolism may have a role in developing
HCC.59 Under cholestatic conditions, conjugated bile acids can activate the S1PR2 and the AKT and ERK1/2
signaling pathways and play a critical role in promoting invasive growth of cholangiocarcinoma, as shown in the
mouse model.60 Primary sclerosing cholangitis (PSC) combined with inflammatory bowel disease (IBD) has a high
risk of developing colon cancer with a cumulative risk of 50% after 25 years of illness, ie, 5-fold higher than in IBD
without PSC, possibly due to exposure of the colon to toxic bile.

Bile Acid Diarrhea (BAD) or Choleraic Diarrhea
Bile acids can cause diarrhea by increasing colonic mucosal permeability, stimulating the colonic mucosa to secrete water
and electrolytes, and accelerating colon motility by enhancing propulsive high amplitude colonic contractions.61 Patients
generally present with chronic or intermittent watery diarrhea, nocturnal bowel movements, fecal incontinence, abdom
inal pain, and flatulence.62 The prevalence of BAD is over 1% in the general population of the western world.63 BAD is
classified as type 1, type 2, and type 3 BAD.
Type 1 BAD is due to ileal resection or ileal dysfunction. >90% of the patients have ileal resection due to Crohn’s
disease, and many patients have unresected ileal inflammatory Crohn’s disease or radiation enteritis.
Type 2 BAD is idiopathic. However, recent work suggests that this condition results from excessive bile acid
production due to defective negative feedback inhibition of bile acid synthesis due to deficiency of FGF19. 33% of
diarrhea-predominant irritable bowel syndrome (IBS-D) patients have type 2 BAD.64
Type 3 BAD is due to gastrointestinal diseases that affect absorption but do not cause ileal dysfunction. These include
small intestinal bacterial overgrowth (SIBO), post-cholecystectomy, post-vagotomy, chronic pancreatitis, celiac disease,
and microscopic colitis.65 Metformin can cause BAD by inhibiting bile acid absorption from the terminal ileum and
increasing hepatic bile acid synthesis.66

Diagnosis of BAD
The following tests are currently used to diagnose BAD.
1. (75) Selenium homocholic acid taurine (75SeHCAT) 7-day retention test: 75SeHCAT is a gamma radiolabeled
synthetic bile acid resistant to bacterial degradation and utilizes the same enterohepatic circulation as natural bile
acids. The patient swallows a capsule of 75SeHCAT, which gets distributed in the gut in an hour. After 1 hour,
a baseline abdominal and pelvic gamma camera scan is done, representing 100% retention. A follow-up gamma
camera scan is done on day 7, and its radioactivity is divided by the radioactivity detected at the baseline scan.
This value indicates retention of 75SeHCAT in the body. In healthy subjects, there should be a retention of ≥15%.
10 −15% retention indicates mild BAD, 5–10% retention moderate BAD, and <5% retention severe BAD.67
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Although the 75SeHCAT retention test is considered the gold standard test to diagnose BAD, it is not available in
the United States but is used in many European countries.
Fasting serum 7αC4 (7 α-hydroxy-4-cholesten-3-one) level: 7αC4 is an intermediate product in bile acid synthesis
secondary to the activity of CYP7A1 and correlates well with bile acid synthesis.68 In patients with chronic
diarrhea, fasting serum 7αC4 of ≥52.5 ng/mL may suggest BAD.69
Fecal bile acid test: The patient is instructed to eat a diet containing 100 grams of fat for 2 days. Then stools are collected in
a kit for 48 hours and kept frozen to maintain bile acid stability. The stool sample is then mailed to the reference laboratory,
where fecal bile acid is measured by high-performance liquid chromatography and mass spectrometry. The total and
individual primary and secondary bile acids can be measured. Currently, BAD is diagnosed if (a) the total fecal bile acid is
>2337µmol/48hours, or (b) the primary fecal bile acid level is more than 10% (without elevated total fecal BAs), or (c) total
fecal bile acid is more than 1000µmol/48hours plus primary fecal bile acids is more than 4%.70
Serum Fibroblast Growth Factor 19 (FGF19): Serum FGF-19 is low in a prospective clinical study.71 It is an
Enzyme-Linked Immunosorbent Assay (ELISA) and can be used as a screening test in patients with BAD. Fasting
serum FGF19 levels of ≤61.7pg/mL can be diagnostic for bile acid diarrhea.72
Therapeutic trial: At present, a therapeutic trial with bile acid binders is most commonly used to diagnose BAD.
They bind to bile acids in the intestinal lumen preventing exposure of the colon to free bile acids.

Management of BAD
Bile acid binders or bile acid sequestrants like cholestyramine, colestipol, or colesevelam are the mainstays of BAD
treatment. They are effective irrespective of the type of BAD. If the patient is intolerant to one bile acid binder, it should
be switched to another bile acid binder. As bile acid binders can bind other medications, patients should take those
medications 1 hour before or 4–6 hours after the intake of bile acid binders. If bile acid binders fail, obeticholic acid,
liraglutide, or octreotide can be tried to control BAD.73,74 Physicians should treat the underlying cause or associated diseases.
Patients with Crohn’s ileitis should be treated with steroids which can induce the expression of ASBT.75 Patients with SIBO
should be treated with antibiotics. Microscopic colitis is generally treated with budesonide. Patients with diarrhea and
steatorrhea due to ileal resection should also be treated with a low-fat diet, medium-chain triglyceride, and fat-soluble
vitamins (A, D, E, and K). Patients with pancreatic insufficiency should be treated with pancreatic enzyme supplementation.

Bile Acid and Malignancy
The role of bile acid in the development and progression of esophageal, gastric, hepatocellular, and cholangiocarcinoma
has been discussed. Bile acids, particularly secondary bile acids, play a role in the initiation and progression of colon
cancer. The possible mechanisms include colonic epithelial damage followed by inflammation and hyperproliferation of
colonic epithelial cells, stimulation of reactive oxygen species with oxidative damage to the DNA and genomic
instability, damage to the p53 gene, resistance to apoptosis, stimulation of β-catenin and multiple oncogenic signaling,
and enhancement of angiogenesis.76

Diagnostic Roles of Bile Acid and Bile Acid Modulation
Intrahepatic Cholestasis of Pregnancy
In the late 2nd trimester and 3rd trimester of pregnancy, serum bile acid measurement can be very useful when patients
present with pruritus. It can give a clue to the early diagnosis of intrahepatic cholestasis of pregnancy when other liver
parameters can be normal.77

Hepatobiliary Diseases
As bile acids escape the enterohepatic circulation in hepatobiliary diseases, elevated serum bile acids can also be
a sensitive diagnostic indicator of these diseases.78 If this test is performed 2 hours postprandially, the sensitivity of this
test can be further increased.79
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Cirrhosis of Liver
Total and individual bile acids, particularly primary conjugated bile acids, can be used as noninvasive markers in the
diagnosis and prognosis of cirrhosis of the liver as well as potential indicators of the development of hepatocellular
carcinoma (HCC) in early cirrhosis of the liver.80 The risk of HCC is increased when there is an elevated serum concentration
of primary bile acids and taurine-conjugated bile acid but a reduced concentration of secondary bile acids.81

BAD
The 14C-glycocholate (14C-BA) breath and stool test was used in the past for detecting SIBO and BAD but is not used
nowadays because of its radiation exposure and availability of better tests.82 Instead, 75SeHCAT 7 day retention test is
used in diagnosing BAD.

Liver Transplantation
After orthotopic liver transplantation, serum bile acid reflects the grafted liver function. Serum bile acid monitoring can
be helpful in the early recognition of graft dysfunction after orthotopic liver transplantation.83

Therapeutic Roles of Bile Acid and Bile Acid Modulation
Ursodeoxycholic Acid (UDCA) or Ursodiol
It is a hydrophilic secondary bile acid found in human and other mammalian bile, although it was first discovered in bear bile,
deriving its name from Ursus, ie, bears. It is an epimer of chenodeoxycholic acid. It is widely used as the drug of first choice in
different cholestatic liver diseases, where it works on multiple pathogenic mechanisms. It protects the injured cholangiocytes
from the toxic effects of bile acids. It detoxifies hydrophobic bile acids. It stimulates impaired hepatobiliary secretion. It protects
hepatocytes from bile acid-induced apoptosis. In primary biliary cholangitis (PBC), UDCA improves the liver function and
delays the progression of the disease to develop severe fibrosis or cirrhosis of the liver, leading to prolongation of transplant-free
survival.84 It also suppresses immunity by interfering with T cell and B cell function. UDCA improves liver chemistry in primary
sclerosing cholangitis but does not improve survival. UDCA has also been used in other cholestatic liver diseases like intrahepatic
cholestasis of pregnancy, graft vs host disease, cystic fibrosis, and progressive familial intrahepatic cholestasis (PFIC).85
UDCA decreases cholesterol absorption from the gut, biliary cholesterol saturation, and biliary lithogenic index (a
measure of cholesterol micellar solubility). UDCA is a safe and effective treatment in dissolving small (≤5 mm in
diameter) cholesterol-rich and radiolucent stones in a functioning gallbladder.86

Obeticholic Acid (OCA)
It is a synthetic derivative of chenodeoxycholic acid. It acts as a selective and potent agonist of FXR, mainly present in
enterocytes and hepatocytes. Its binding potency to FXR is more than 100 fold higher than natural bile acids.87 OCA was
approved for the treatment of PBC a few years ago. OCA can decrease bile acid production by increasing the synthesis of FGF19.
OCA can also improve hepatic bile acid excretion by stimulating BSEP. Thus, OCA can reduce toxic bile build-up in PBC.88

Bile Acid Sequestrants (BAS)
These include cholestyramine, colestipol, and colesevelam. They have been used in various clinical conditions:
(a) Hyperlipidemia. BAS can bind bile acids and bile salts in the small bowel. As a result, the enterohepatic
circulation of bile acids is interrupted, and there is increased conversion of cholesterol into bile acid, depleting
intrahepatic cholesterol. This effect leads to increased low-density lipoprotein (LDL) receptor formation.
Upregulation of LDL receptors causes catabolism of LDL and decreases serum LDL levels. BAS is mainly
used in patients with hyperlipidemia where the primary abnormality is increased LDL-C. BAS can also reduce
coronary artery disease progression and outcome.89
(b) Cholestatic liver diseases. BAS is used as an anti-pruritic agent in cholestatic liver diseases.
(c) BAS is considered the first-line BAD agent.90
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Ileal Bile Acid Transport Inhibitors (IBATis)
IBATis prevent bile acid reuptake from the ileal lumen into the terminal ileal enterocytes by inhibiting ASBT. This leads to (a)
increased bile acid delivery into the colon where bile acid increases colonic secretory and motor activity, (b) increased bile acid
synthesis in the liver because of decreased ileal FXR activation by bile acids and reduced synthesis of FGF19 This is evidenced by
increased serum bile acid precursor C4 (7α-hydroxy-4-cholesten-3-one), (c) decreased serum total cholesterol and LDL
cholesterol as increased bile acid synthesis consumes cholesterol stores in the liver and depletion of cholesterol stores promotes
expression of cholesterol receptors on the hepatocytes, (d) improvement of liver histology in mouse models of cholestatic liver
diseases and non-alcoholic steatohepatitis (NASH) due to interruption of enterohepatic circulation and decreased bile acid
pool,91,92 (e) increased serum level of glucagon-like peptide-1 (GLP-1) probably due to the effect of bile acids on enteroendocrine
L cells93 and (f) decreased severity and incidence of necrotizing enterocolitis in premature rats.94 As a result, IBATis have the
potential of treating chronic constipation, cholestatic liver disease, non-alcoholic fatty liver disease (NAFLD), NASH, athero
sclerosis, type II diabetes mellitus, and necrotizing enterocolitis.95 IBATi blocks ASBT not only on ileal enterocytes but also on the
renal tubules and thus increases bile acid output both by fecal and renal excretion. Several IBATis are being investigated in clinical
trials for different indications. In September 2021, Food and Drug Administration (FDA) in the United States approved
Maralixibat (Livmarli) oral solution as the first and only medication for treating cholestatic pruritus in patients with Alagille
syndrome one year of age and older. In July 2021, FDA approved Odevixibat (Bylvay) as the first treatment for pruritus in patients
with PFIC. In 2018, Elobixibat (Goofice) was approved in Japan to treat chronic idiopathic constipation.

TGR5 Agonist
6g (2-thio-imidazole derivative) is a selective and potent oral TGR5 agonist that stimulates GLP-1 secretion. It has
a robust glucose-lowering effect in the mouse model.96 It can also reduce obesity and hepatic steatosis by controlling
mice’s blood glucose. In recent years, TGR5 agonist has been a therapeutic target in different metabolic diseases,
including type II diabetes mellitus, NAFLD, obesity, atherosclerosis, and malignancy.97
In the mouse model, engineered FGF19 was found to have anti-steatotic, anti-inflammatory, and anti-fibrotic proper
ties with a resolution of histologic features of NASH.98

Future Role of Bile Acids as Therapeutic Agents in Cancer
Synthetic derivatives of CDCA (HS-1199 and HS-1200) and UDCA (HS-1183) can inhibit cell growth and induce
apoptosis in cancer cells. These agents have anti-tumor activity in gastric cancer, HCC, breast cancer, cervical cancer,
prostate cancer, and T-cell leukemia.99–104

Future Role of Bile Acids as Drug Absorption Enhancer
Because of the unique amphipathic structure and physicochemical properties, bile acids or modified bile acids can
solubilize and enhance absorption of many drugs from the terminal ileum, buccal mucosa, nasal mucosa, cornea, skin and
rectum, and thus improve bioavailability of many drugs as shown in many experimental animals and humans.105–107

Summary
Bile is an essential body fluid produced in our liver. It has a unique composition of fluid, organic and inorganic materials. The
enterohepatic circulation is an efficient mechanism of preserving its contents. Bile production and bile flow are under neuro
hormonal control. The primary function of bile is the excretion of cholesterol and bilirubin from the liver and digestion and
absorption of fat and fat-soluble vitamins from the small bowel. Bile acids can control their synthesis in the liver and have many
endocrine and metabolic functions. Bile acids work through the nuclear receptor FXR and membrane receptor TGR5. By
activating FXR, bile acids (1) controls hepatic bile acid synthesis via the formation of FGF-19, (2) keeps intracellular bile acid
level low by inhibiting NTCT and activating BSEP and thus helps in detoxification in the liver, and (3) controls glucose
metabolism by stimulating glycogen synthesis, inhibiting gluconeogenesis and increasing insulin sensitivity. Through the
activation of TGR5, bile acids (1) lower blood glucose by stimulating GLP-1 secretion from L cells in the ileocolonic mucosa
and by releasing insulin directly from pancreatic β cells (2) stimulate chloride secretion from the gallbladder, (3) enhance
gallbladder refilling by smooth muscle relaxation, (4) protect intestinal epithelial barrier and (5) reduce intestinal inflammation.
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Bile acids also have potent antimicrobial activity in the intestine. They also help maintain the intestinal microbiome. Serum bile
acid is markedly increased in cholestatic conditions and other liver diseases, including acute viral hepatitis, cirrhosis, HCC, liver
failure, hemochromatosis, portal vein thrombosis, Budd-Chiari syndrome, portosystemic shunts, and Wilson disease. Lithogenic
bile has an increased propensity to develop gallstones. It can be found in pregnant women, obese individuals, persons taking
a high-calorie diet, patients with ileal disease or resection with bile salt depletion, and patients on certain medications like nicotinic
acid and clofibrate. After cholecystectomy, hepatic bile synthesis increases, and the colon’s exposure to secondary bile acids
causes diarrhea. Terminal ileal disease or resection of less than 100 cm may cause BAD, whereas terminal ileal disease or resection
of more than 100 cm may cause steatorrhea. DGR can cause gastric ulceration, chronic gastritis, gastric atrophy, and intestinal
metaplasia. DGR is also considered a risk factor for developing gastric cancer. DGR can be seen during endoscopy, but a more
objective diagnosis can be made by DISIDA scan, HIDA scan, or Bilitec device. DGER, along with acid reflux, may injure the
esophageal mucosa, including the formation of Barrett’s esophagus, and Bilitec in combination with 24 hours esophageal pH
should be done to diagnose it. Cholestasis is characterized by the retention of bile acids, bilirubin, and other bile contents that
would normally be excreted in bile. Retained bile acids are toxic to hepatocytes and cholangiocytes and may cause hepatic fibrosis,
cirrhosis, hepatoma, and cholangiocarcinoma in long-standing cases. BAD is due to the secretagogue and colonic prokinetic
property of bile acids. BAD is diagnosed by therapeutic trials, elevated fasting serum 7αC4, low serum FGF19, elevated fecal bile
acids and elevated 75SeHCAT 7-day retention test. BAD is managed by BAS and treatment of the underlying cause. Serum bile
acid can be a valuable marker of intrahepatic cholestasis of pregnancy, cirrhosis of the liver, and hepatocellular carcinoma. UDCA
is used in different cholestatic liver diseases and dissolves small cholesterol gallstones. Obeticholic acid delays the progression of
PBC. BAS is used in BAD and hyperlipidemia, and cholestatic liver diseases. IBATi is used to treat constipation and cholestatic
pruritus in Alagille syndrome and PFIC. However, they have the potential of treating NAFL, NASH, type 2 diabetes mellitus,
atherosclerosis, and necrotizing enterocolitis. TGR5 agonists can control blood glucose and reduce obesity and NAFLD.
Synthetic derivatives of CDCA and UDCA have anti-tumor activity and can be used as potential therapeutic agents against
different malignancies in the future.
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